GoAI
Get started
Delcath Systems, Inc. logo

Delcath Systems, Inc.

DCTH

NASDAQHealthcareMedical - Devices

Open in GoAI

Previous close

$17.14

+$0.39 · +2.33%

Aug 21, 4:00 PM ET

DCTH company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

72

Undervalued

Momentum

65

Gaining

Sentiment

49

Mixed

Risk resilience

63

Moderate Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Delcath Systems, Inc. is an interventional oncology firm operating in the United States and Europe, dedicated to developing treatments for both primary and secondary liver cancers. Its leading investigational product is the HEPZATO KIT, a unique hepatic delivery system for melphalan that targets high-dose chemotherapy specifically to the liver. This innovative approach aims to substantially reduce systemic drug exposure and mitigate associated side effects. HEPZATO's clinical evaluation is advancing through the FOCUS trial, which is designed to assess the objective response rate in individuals with metastatic uveal melanoma whose disease is primarily concentrated in the liver. Furthermore, the company offers a separate version of HEPZATO as a medical device in Europe, marketed under the CHEMOSAT Hepatic Delivery System brand (or simply CHEMOSAT). This system empowers European medical centers to manage a diverse array of liver cancer conditions. Delcath Systems, Inc. was established in 1988, with its corporate headquarters situated in New York, New York.

Industry
Medical - Devices
Sector
Healthcare
Headquarters
US
CEO
Gerard J. Michel
Listed since
May 3, 2018
Employees
156

Market position

Day range

Current $17.14

52-week range

Current $17.14

Open
$16.91
Previous close
$16.75
Volume
509.06K
0.98× average
Average volume
520.21K
Average daily volume
Market cap
591.7M USD
Beta
0.52
Market reference 1
50-day average
$13.5225
+26.75% above average
200-day average
$10.8705
+57.67% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
319.28M USD
P/E (TTM)
1,558.18×
P/B (TTM)
5.08×
P/S (TTM)
6.2×
EV / EBITDA
82.74×
Earnings yield
0.75%
Free cash flow yield
5.80%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
87.05%
Operating margin
-1.90%
Net margin
0.56%
Return on equity
2.43%
Return on assets
2.18%
Return on invested capital
0.45%

Financial health

Debt / equity
0.02×
Current ratio
10.92×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends326%-632%-1590%-2548%Gross margin, FY2021: 81.13%Gross margin, FY2022: 74.77%Gross margin, FY2023: 69.25%Gross margin, FY2024: 83.37%Gross margin, FY2025: 86.16%Operating margin, FY2021: -690.04%Operating margin, FY2022: -1245.05%Operating margin, FY2023: -1849.01%Operating margin, FY2024: -33.36%Operating margin, FY2025: 0.77%Net margin, FY2021: -721.49%Net margin, FY2022: -1342.70%Net margin, FY2023: -2308.86%Net margin, FY2024: -70.92%Net margin, FY2025: 3.17%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 81.13%. Gross margin FY2022 74.77%. Gross margin FY2023 69.25%. Gross margin FY2024 83.37%. Gross margin FY2025 86.16%. Operating margin FY2021 -690.04%. Operating margin FY2022 -1245.05%. Operating margin FY2023 -1849.01%. Operating margin FY2024 -33.36%. Operating margin FY2025 0.77%. Net margin FY2021 -721.49%. Net margin FY2022 -1342.70%. Net margin FY2023 -2308.86%. Net margin FY2024 -70.92%. Net margin FY2025 3.17%.

Income trends

Revenue

85.23M USD+129.08%

Operating income

660K USD+13.07M USD

Net income

2.7M USD+29.09M USD
Income trends across reported periods98.52M USD45.36M USD−7.81M USD−60.97M USDRevenue, FY2021: 3.56M USDRevenue, FY2022: 2.72M USDRevenue, FY2023: 2.07M USDRevenue, FY2024: 37.21M USDRevenue, FY2025: 85.23M USDOperating income, FY2021: −24.53M USDOperating income, FY2022: −33.85M USDOperating income, FY2023: −38.18M USDOperating income, FY2024: −12.41M USDOperating income, FY2025: 660K USDNet income, FY2021: −25.65M USDNet income, FY2022: −36.51M USDNet income, FY2023: −47.68M USDNet income, FY2024: −26.39M USDNet income, FY2025: 2.7M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 3.56M USD. Revenue FY2022 2.72M USD. Revenue FY2023 2.07M USD. Revenue FY2024 37.21M USD. Revenue FY2025 85.23M USD. Operating income FY2021 −24.53M USD. Operating income FY2022 −33.85M USD. Operating income FY2023 −38.18M USD. Operating income FY2024 −12.41M USD. Operating income FY2025 660K USD. Net income FY2021 −25.65M USD. Net income FY2022 −36.51M USD. Net income FY2023 −47.68M USD. Net income FY2024 −26.39M USD. Net income FY2025 2.7M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue85.23M USD37.21M USD2.07M USD2.72M USD3.56M USD
Cost of goods sold11.8M USD6.19M USD635K USD686K USD671K USD
Gross profit73.43M USD31.02M USD1.43M USD2.03M USD2.88M USD
Research and development29.25M USD13.87M USD17.5M USD18.58M USD13.78M USD
Selling, general, and administrative43.53M USD29.55M USD22.11M USD17.3M USD13.64M USD
Operating expenses72.77M USD43.43M USD39.61M USD35.89M USD27.42M USD
Interest income2.92M USD125K USD———
Interest expense——1.44M USD2.69M USD1.19M USD
Depreciation and amortization349K USD229K USD399K USD132K USD146K USD
Operating income660K USD−12.41M USD−38.18M USD−33.85M USD−24.53M USD
Net income2.7M USD−26.39M USD−47.68M USD−36.51M USD−25.65M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
64%
7 beats, 2 misses, 2 met estimates
Average EPS surprise
+52.78%
11 comparable reports
Latest EPS result
0.07
Estimate -0.09 · Beat by 178.53%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates0.140.05-0.05-0.14Q1 '25BeatQ2 '25MissQ3 '25BeatQ4 '25MetQ1 '26BeatQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Mar 6, 2025: actual 0.05, estimate -0.1, surprise +150.00%, Beat. Q2 2025, reported May 8, 2025: actual 0.03, estimate 0.1, surprise -70.00%, Miss. Q3 2025, reported Aug 6, 2025: actual 0.07, estimate 0.026, surprise +169.23%, Beat. Q4 2025, reported Nov 4, 2025: actual 0.02, estimate 0.02, surprise 0.00%, Met estimate. Q1 2026, reported Feb 26, 2026: actual -0.05, estimate -0.063, surprise +20.62%, Beat. Q2 2026, reported May 7, 2026: actual -0.03, estimate -0.094, surprise +68.09%, Beat. Q3 2026, reported Aug 6, 2026: actual 0.07, estimate -0.089, surprise +178.53%, Beat. Q4 2026, reported Nov 3, 2026: actual —, estimate -0.1, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates30.3M24.84M19.39M13.93MQ1 '25MissQ2 '25BeatQ3 '25BeatQ4 '25BeatQ1 '26BeatQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Mar 6, 2025: actual 15.1M USD, estimate 16.67M USD, surprise -9.43%, Miss. Q2 2025, reported May 8, 2025: actual 19.78M USD, estimate 18.65M USD, surprise +6.11%, Beat. Q3 2025, reported Aug 6, 2025: actual 24.16M USD, estimate 23.02M USD, surprise +4.92%, Beat. Q4 2025, reported Nov 4, 2025: actual 20.56M USD, estimate 20.35M USD, surprise +1.03%, Beat. Q1 2026, reported Feb 26, 2026: actual 20.73M USD, estimate 20.58M USD, surprise +0.74%, Beat. Q2 2026, reported May 7, 2026: actual 25M USD, estimate 23.51M USD, surprise +6.34%, Beat. Q3 2026, reported Aug 6, 2026: actual 29.13M USD, estimate 26.25M USD, surprise +10.97%, Beat. Q4 2026, reported Nov 3, 2026: actual —, estimate 26M USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Rating distribution

11 ratings
Strong buy00%
Buy873%
Hold218%
Sell19%
Strong sell00%

DCTH news

zacks.com

Delcath Systems (DCTH) Is a Great Choice for 'Trend' Investors, Here's Why

If you are looking for stocks that are well positioned to maintain their recent uptrend, Delcath Systems (DCTH) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength"…

Read source
zacks.com

Here's Why Delcath Systems, Inc. (DCTH) is a Great Momentum Stock to Buy

Does Delcath Systems, Inc. (DCTH) have what it takes to be a top stock pick for momentum investors? Let's find out.

Read source
zacks.com

Does Delcath Systems (DCTH) Have the Potential to Rally 42.77% as Wall Street Analysts Expect?

The average of price targets set by Wall Street analysts indicates a potential upside of 42.8% in Delcath Systems (DCTH). While the effectiveness of this highly sought-after metric is questionable, the positive trend in…

Read source
seekingalpha.com

Delcath Systems, Inc. (DCTH) Q2 2026 Earnings Call Transcript

Delcath Systems, Inc. (DCTH) Q2 2026 Earnings Call Transcript

Read source
marketbeat.com

Delcath Systems Q2 Earnings Call Highlights

Delcath Systems NASDAQ: DCTH reported second-quarter 2026 revenue of $29.1 million, up from $24.2 million a year earlier, as growth in HEPZATO KIT sales supported continued commercial expansion and investment in clinical…

Read source
zacks.com

Delcath Systems, Inc. (DCTH) Tops Q2 Earnings and Revenue Estimates

Delcath Systems, Inc. (DCTH) came out with quarterly earnings of $0.07 per share, beating the Zacks Consensus Estimate of a loss of $0.16 per share. This compares to earnings of $0.07 per share a year ago.

Read source

DCTH peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding DCTH

Funds reporting this stock among their holdings, ordered by reported position size.

iShares Russell 2000 ETF logoiShares Russell 2000 ETFIWM
Market value
12.49M
Weight
0.02%
AUM
81.62B USD
Expense ratio
0.19%
Price / 1D
$299.96+0.77%
Vanguard Morningstar Total Stock Market ETF logoVanguard Morningstar Total Stock Market ETFVTI
Market value
10.87M
Weight
0.00%
AUM
2.3T USD
Expense ratio
0.03%
Price / 1D
$378.24+0.44%
Simplify Propel Opportunities ETF logoSimplify Propel Opportunities ETFSURI
Market value
4.48M
Weight
5.26%
AUM
85.05M USD
Expense ratio
2.82%
Price / 1D
$19.8186-0.20%
iShares Russell 2000 Value ETF logoiShares Russell 2000 Value ETFIWN
Market value
3.82M
Weight
0.03%
AUM
14.66B USD
Expense ratio
0.24%
Price / 1D
$224.81+0.45%
Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
3.72M
Weight
0.00%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$245.53+0.82%
Vanguard Russell 2000 ETF logoVanguard Russell 2000 ETFVTWO
Market value
1.97M
Weight
0.01%
AUM
17.4B USD
Expense ratio
0.06%
Price / 1D
$121.25+0.74%
iShares Micro-Cap ETF logoiShares Micro-Cap ETFIWC
Market value
1.66M
Weight
0.11%
AUM
1.53B USD
Expense ratio
0.60%
Price / 1D
$198.39+1.10%
Dimensional - US Small Cap ETF logoDimensional - US Small Cap ETFDFAS
Market value
1.18M
Weight
0.01%
AUM
15.92B USD
Expense ratio
0.26%
Price / 1D
$83.02+0.73%

Continue in GoAI

Research DCTH

research.disclaimer